These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17094436)

  • 21. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer.
    Bryan JN; Jia F; Mohsin H; Sivaguru G; Miller WH; Anderson CJ; Henry CJ; Lewis MR
    Nucl Med Biol; 2005 Nov; 32(8):851-8. PubMed ID: 16253810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
    Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
    J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
    Garrison JC; Rold TL; Sieckman GL; Naz F; Sublett SV; Figueroa SD; Volkert WA; Hoffman TJ
    Bioconjug Chem; 2008 Sep; 19(9):1803-12. PubMed ID: 18712899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
    Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
    J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
    Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
    Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice.
    Lo WL; Liang CH; Chen LC; Lee SY; Lo SN; Chen MW; Lu RM; Liu IJ; Wu HC; Chang CH
    Appl Radiat Isot; 2020 Jul; 161():109162. PubMed ID: 32561130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
    Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake.
    Froidevaux S; Calame-Christe M; Tanner H; Eberle AN
    J Nucl Med; 2005 May; 46(5):887-95. PubMed ID: 15872364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
    Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
    Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis.
    Froidevaux S; Calame-Christe M; Tanner H; Sumanovski L; Eberle AN
    J Nucl Med; 2002 Dec; 43(12):1699-706. PubMed ID: 12468522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
    Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
    Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung.
    Traub T; Petkov V; Ofluoglu S; Pangerl T; Raderer M; Fueger BJ; Schima W; Kurtaran A; Dudczak R; Virgolini I
    J Nucl Med; 2001 Sep; 42(9):1309-15. PubMed ID: 11535718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
    Smith-Jones PM; Bischof C; Leimer M; Gludovacz D; Angelberger P; Pangerl T; Peck-Radosavljevic M; Hamilton G; Kaserer K; Kofler A; Schlangbauer-Wadl H; Traub T; Virgolini I
    Endocrinology; 1999 Nov; 140(11):5136-48. PubMed ID: 10537142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.